Caliway Biopharmaceuticals Co., Ltd. (TPE:6919)
Taiwan
· Delayed Price · Currency is TWD 135.50
+1.00 (0.74%)
Aug 14, 2025, 1:30 PM CST
TPE:6919 Cash Flow Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 |
| Net Income | -618.09 | -588.83 | -488.46 | -286.16 | -224.29 | -98.49 | Upgrade
|
| Depreciation & Amortization | 30.11 | 29.51 | 27.87 | 25.34 | 23.28 | 18.21 | Upgrade
|
| Loss (Gain) From Sale of Assets | - | - | - | 0.11 | - | - | Upgrade
|
| Stock-Based Compensation | 170.59 | 65.05 | 22.98 | 19.71 | 74.76 | 8.28 | Upgrade
|
| Other Operating Activities | -5.11 | -6.69 | -0.35 | -0.36 | -3.27 | 0.86 | Upgrade
|
| Change in Accounts Receivable | 4.32 | 2.71 | -4.77 | -3.12 | - | 3.2 | Upgrade
|
| Change in Inventory | -1.66 | -1.84 | 1.78 | -2.76 | 2.48 | -2.51 | Upgrade
|
| Change in Accounts Payable | -1.72 | -0.73 | -0.83 | 2.21 | -0.41 | -0.3 | Upgrade
|
| Change in Unearned Revenue | -1.7 | 2.59 | -3.47 | 4.5 | - | - | Upgrade
|
| Change in Other Net Operating Assets | -34.91 | -24.08 | 21.32 | -2.22 | 16.77 | 23.51 | Upgrade
|
| Operating Cash Flow | -458.16 | -522.31 | -423.94 | -242.76 | -110.7 | -47.24 | Upgrade
|
| Capital Expenditures | -9.73 | -10 | -8.6 | -14.16 | -14.9 | -2.31 | Upgrade
|
| Sale of Property, Plant & Equipment | - | - | - | 0 | - | - | Upgrade
|
| Sale (Purchase) of Intangibles | -0.6 | -1.09 | -1.09 | - | - | - | Upgrade
|
| Investment in Securities | -1,137 | -2,478 | 166.78 | -456.18 | - | - | Upgrade
|
| Other Investing Activities | - | - | 0.01 | -0.2 | - | - | Upgrade
|
| Investing Cash Flow | -1,147 | -2,489 | 157.09 | -470.54 | -14.9 | -2.31 | Upgrade
|
| Long-Term Debt Issued | - | - | - | - | - | 8.13 | Upgrade
|
| Total Debt Issued | - | - | - | - | - | 8.13 | Upgrade
|
| Short-Term Debt Repaid | - | - | - | - | - | -5 | Upgrade
|
| Long-Term Debt Repaid | - | -8.58 | -8.22 | -12.6 | -93.98 | -27.83 | Upgrade
|
| Total Debt Repaid | -8.79 | -8.58 | -8.22 | -12.6 | -93.98 | -32.83 | Upgrade
|
| Net Debt Issued (Repaid) | -8.79 | -8.58 | -8.22 | -12.6 | -93.98 | -24.7 | Upgrade
|
| Issuance of Common Stock | 6,508 | 6,499 | 3,042 | 784.32 | 720.88 | 147.43 | Upgrade
|
| Repurchase of Common Stock | - | - | - | - | -0.09 | - | Upgrade
|
| Other Financing Activities | 30.1 | 0.52 | - | - | - | - | Upgrade
|
| Financing Cash Flow | 6,529 | 6,491 | 3,034 | 771.72 | 626.81 | 122.74 | Upgrade
|
| Foreign Exchange Rate Adjustments | -0.83 | -0.11 | 0.32 | 1.73 | 0.14 | -1.32 | Upgrade
|
| Net Cash Flow | 4,923 | 3,479 | 2,767 | 60.15 | 501.35 | 71.87 | Upgrade
|
| Free Cash Flow | -467.9 | -532.31 | -432.54 | -256.93 | -125.6 | -49.55 | Upgrade
|
| Free Cash Flow Margin | -1043.66% | -1197.97% | -1111.01% | -2004.12% | -1017.90% | -478.70% | Upgrade
|
| Free Cash Flow Per Share | -0.32 | -0.37 | -0.35 | -0.22 | -0.14 | -0.07 | Upgrade
|
| Cash Interest Paid | 0.25 | 0.33 | 0.5 | 0.67 | 6.18 | 3.65 | Upgrade
|
| Cash Income Tax Paid | - | - | - | - | 0.03 | 0.09 | Upgrade
|
| Levered Free Cash Flow | -241.58 | -391.26 | -266.4 | -171.06 | -74 | -19.88 | Upgrade
|
| Unlevered Free Cash Flow | -241.43 | -391.05 | -266.09 | -170.65 | -72.19 | -17.06 | Upgrade
|
| Change in Working Capital | -35.66 | -21.35 | 14.03 | -1.4 | 18.84 | 23.9 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.